A Study to Examine the Efficacy of a Therapeutic THX-110 for Tourette Syndrome

Neurothera Labs Inc.60 enrolled

Overview

This study evaluates the efficacy and safety of THX-110 in the management of tics and other symptoms (e.g. rage attacks, anxiety, depression, sleep difficulties) in patients with Tourette syndrome. In the first part of the study, half of the patients will receive THX-110, while the other half will receive a placebo. After completion of the first study part, patients will have the opportunity to continue into the second part of the study. In this part, all participants will receive THX-110.

THX-110 is an investigational drug and is being developed for the treatment of patients with Tourette syndrome and other conditions. THX-110 consists of an active substance from cannabis (dronabinol, tetrahydrocannabinol, THC) and PEA, a substance that occurs naturally in the human body, in animals and plants. Dronabinol and similar active substances are already approved in some countries for the treatment of other conditions. In some countries, various cannabis-based medications are currently being used in the treatment of patients with Tourette syndrome, mostly without official approval. PEA has already been used and well tolerated in numerous clinical trials. The combination of PEA and dronabinol is assumed to show better efficacy compared to treatment with dronabinol alone. The planned study will evaluate the efficacy of THX-110 in the management of tics and other symptoms in patients with Tourette syndrome. Other objectives are to assess study drug dosage and to identify side effects that may be associated with the study drug. In the first part of the study, half of the patients will receive THX-110, while the other half will receive a placebo. The treatment phase will last 12 weeks. After completion of the first part, patients can decide if they want to participate in the second part of the study. In this optional second part of the study, all patients will receive THX-110 for 12 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Tourette Syndrome

Interventions

THX-110 (dronabinol plus PEA)DRUG

2.5 mg dronabinol capsules and 400 mg PEA tablets

PlaceboDRUG

Sesame oil pill manufactured to mimic 2.5 mg dronabinol capsules; cellulose pill manufactured to mimic 400 mg PEA tablets

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Tourette syndrome according to DSM-5 2. Male and female subjects with an age between ≥18 and \<65 years 3. Total tic score (TTS) of the YGTSS \>18 4. CGI-S ≥4 5. Medication (and stimulation parameters for deep brain stimulation) for tics and comorbidities must be on a stable dose for at least 6 weeks before entering the study and subject must consent to maintain the stable dose during the study 6. Signed written informed consent and willingness to comply with treatment and follow-up procedures 7. Subjects capable of understanding the investigational nature, potential risks and benefits of the clinical study 8. Women of child-bearing potential must have a negative pregnancy test (i.e., negative for urine human chorionic gonadotropin \[hCG\]) before first treatment with study medication. They must practice a highly effective, reliable and medically approved contraceptive regimen during the study (e.g., theoretical failure rate less than 1% per year a when used consistently and correctly), which include oral or parenteral or implanted hormonal contraception, vaginal ring releasing hormonal contraception (e.g., Nuvaring), intrauterine device or intrauterine system. Post-menopausal women may enter this study. Post-menopausal women are defined as those without menses in the past 12 months without an alternative medical cause, and with a serum follicle stimulating hormone (FSH) in the post-menopausal range. Women who are surgically sterile may enter this study with historical documentation of surgical procedure (bilateral tubal ligation or bilateral oophorectomy at least 6 weeks prior screening or hysterectomy or uterine agenesis) and a negative pregnancy test. 9. Male subjects must be willing to use a condom with sexual partners during this study and for a period of three months following the last administration of study medication until the follow-up visit. Male subjects must be willing to abstain from sperm donation for 3 months after the completion of this study. Exclusion Criteria: 1. Comorbid OCD, ADHD, depression, or anxiety disorder when unstable and/or in need of an initial adjustment for a therapy 2. Presence of a comorbid psychiatric condition as developmental disability, psychotic illness or bipolar disorder 3. Ongoing behavioural treatment for tics 4. History of schizophrenia, seizure, psychotic, severe personality, or pervasive developmental disorder 5. Current clinical diagnosis of substance abuse or dependence 6. History of cannabis dependence 7. Secondary and other chronic tic disorders or other significant neurological disorders 8. History of severe cardiac diseases, severe cardiovascular diseases, severe renal disorders, or severe hepatic diseases and/or positive for human immunodeficiency virus (HIV), hepatitis C, or hepatitis B 9. Concomitant medications have to be on stable dose since at least 6 weeks before entering the study and must be well tolerated at baseline without causing dizziness, confusion, sedation, or somnolence such as central nervous system depressants (e.g., barbiturates, benzodiazepines, ethanol, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, muscle relaxants) 10. Use of cannabis or CBM in the 30-day period prior to study entry and/or positive delta-9-THC urine test at baseline 11. Positive pregnancy test, i.e., positive for urine beta-hCG 12. Pregnant or breast-feeding women 13. Subjects who received any investigational medication or used any investigational device within 30 days prior to the first dose of study medication or is actively participating in any investigational drug or device study, or is scheduled to receive an investigational drug or to use an investigational device during the course of the study 14. Subjects with a known allergy, hypersensitivity, or intolerance to the active substances and/or excipients of study medication (e.g., cannabis, cannabinoids, sesame oil) 15. Any condition, which in the opinion of the investigator, would interfere with the evaluation of the study product or poses a health risk to the subject 16. Subjects who are employees of the sponsor or employees or close relatives of the investigator

Locations (2)

Medizinische Hochschule Hannover, Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie

Hanover, Germany

LMU Klinikum der Universität München, Klinik für Psychiatrie und Psychotherapie

Munich, Germany

Outcomes

Primary Outcomes

Change in YGTSS-TTS

Absolute change in YGTSS-TTS as a continuous endpoint at week 12 of the double-blind phase (visit 9) compared to baseline.

Time frame: Baseline and week 12 of the double-blind phase

Secondary Outcomes

Response to treatment according to YGTSS-TTS

Key secondary endpoint is the response to treatment according to YGTSS-TTS, defined as a reduction in YGTSS-TTS of at least 20% (compared to baseline) at week 12 of the double-blind phase (visit 9).

Time frame: Baseline and week 12 of the double-blind phase

YGTSS-TTS as a binary responder criterion and as a continuous endpoint at week 7 of the double-blind phase

Time frame: Baseline and week 7 of the double-blind phase

YGTSS-GS (= YGTSS-TTS + YGTSS-impairment score)

Time frame: Baseline, week 7 and week 12 of the double-blind phase, week 19 and week 24 of the extension open label phase

Modified Rush Video-Based Tic Rating Scale (MRVS)

No. of Body Areas (score 0-4), Motor Tic Frequency (tics/min) (score 0-4) Phonic Tic Frequency (score 0-4) Severity of Motor Tics (score 0-4) Severity of Phonic Tics (score 0-4) Total score (0-20) 0=best, 20=worst

Time frame: Baseline, week 7 and week 12 of the double-blind phase, week 19 and week 24 of the extension open label phase

Clinical Global Impression-Improvement Score (CGI-I)

The CGI-S score obtained at the baseline (initiation) visit serves as a good basis for making this assessment. Only the following one query is rated on a seven-point scale: "Compared to the patient's condition at admission to the project \[prior to medication initiation\], this patient's condition is: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment."

Central Contacts

Kirsten Müller-Vahl, Prof. Dr.

CONTACT

+49 511 532 mueller-vahl.kirsten@mh-hannover.de

Christoph Schindler, Prof. Dr.

CONTACT

+49 511 5350 schindler.christoph@mh-hannover.de

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.